| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology |
Recent Updates
Recently added Catalysts
Privia Health Group, Inc. Common Stock$23.96
+0.17 (+0.71%)
Market Cap
3.02 B
EPS
0.17
P/E Ratio
138.74 $
Value Trade
18.73 M
SEC Financials
Q1 2026Dilution Risk
Revenue
603.85 M
Operating CF
-49.47 M
Total Assets
1.42 B
Total Liabilities
611.99 M
Equity
753.06 M
0.42 %
Week
-12.01 %
1 Month
-0.13 %
3 Month
11.39 %
6 Month
%
5 Year
%
All Time
Cash Data
Cash Position
419.52 M
Monthly Burn
16.49 M
Runway
22.4 mo
Burn Trend
SEC Filing
May 7, 2026
Overview
Volume
1.20 M
52 Week Range
19.08 - 28.82
% held by Insiders
6.69 %
% held by Institutions
92.3 %
Enterprise Value
2.60 B
Total Shares
125.97 M
Short %
3.44 %
Float Shares
107.07 M
Company Description
locked
Upcoming Catalyst
Past FDA Catalysts & PDUFA Decisions
| Date | Drug | Catalyst | Stage | Outcome | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|---|
— | Example Drug | Phase 3 data readout | Phase 3 | — | – | 0% | 0% |
— | Example Drug | Phase 3 data readout | Phase 3 | — | – | 0% | 0% |
— | Example Drug | Phase 3 data readout | Phase 3 | — | – | 0% | 0% |
Drug Pipeline Intelligence
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | The study met its primary endpoint demonstrating statistically significant improvement. Read More | Phase 3 Study Results Announcement | |
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | The study met its primary endpoint demonstrating statistically significant improvement. Read More | Phase 3 Study Results Announcement | |
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | The study met its primary endpoint demonstrating statistically significant improvement. Read More | Phase 3 Study Results Announcement |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in PRVA
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
PRVA Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
| 2026-08-21 | 0.00 | 0 | - | - | - | - | - | - | ||||
| 2026-08-21 | 0.00 | 0 | - | - | - | - | - | - | ||||
| 2026-08-21 | 0.00 | 0 | - | - | - | - | - | - | ||||
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
-PRVA
Aug 6, 2026▲ +0.7%today
Privia Health Reports Strong Second Quarter and Year-to-Date 2026 Results
Privia Health Group, Inc. reported strong financial results for the second quarter and first half of 2026, with a net income of $9.0 million, marking a 236.7% increase from the same period in 2025. The company also reported an adjusted EBITDA of $37.4 million, up 29.1% year-over-year. Additionally, Privia raised its full-year guidance for key financial metrics, indicating positive growth expectations.
Read more →-PRVA
Jul 7, 2026Privia Health to Report Second Quarter 2026 Results on Thursday, August 6
Privia Health Group, Inc. will announce its second-quarter financial results on August 6, 2026, before market opening. The press release will be available at 7:00 am ET, followed by a conference call at 8:00 am ET to discuss the results and future outlook. The company emphasizes its commitment to enhancing healthcare delivery and patient outcomes.
Read more →-PRVA
May 27, 2026Privia Health Enters New Jersey
Privia Health Group, Inc. has announced a partnership with the Neurology Group of Bergen County to enter New Jersey. This collaboration aims to enhance care delivery through the Privia Platform by the end of 2026. The partnership is expected to improve access to high-quality neurological care while maintaining the independent culture of NGBC.
Read more →-PRVA
May 7, 2026Privia Health Reports First Quarter 2026 Financial Results - Strong First Quarter Performance and Operating Execution - Reiterated Full-Year 2026 Guidance Reflects Continued Momentum ARLINGTON, VA
Privia Health Group, Inc. reported its financial results for the first quarter of 2026, showcasing strong performance with a 25.8% increase in total revenue, amounting to $603.8 million. The adjusted EBITDA rose by 36.3% compared to the same quarter last year. While the company reiterated its full-year guidance and raised the range for attributed lives, it experienced a decline in net income and net income per share versus the previous year.
Read more →-PRVA
Mar 24, 2026Privia Health Earns 2026 HFMA MAP Award for Revenue Cycle Excellence
Privia Health Group, Inc. has been awarded the 2026 MAP Award for High Performance in Revenue Cycle by HFMA. This recognition, given for excellence in revenue cycle metrics, marks the ninth time in ten years that Privia has received this honor. The award reflects the company's commitment to patient-centered practices and innovative strategies that enhance operational efficiency.
Read more →-PRVA
Mar 4, 2026Marking National Colorectal Cancer Awareness Month, Privia Health Program Achieves 84% Colorectal Cancer Screening Rate Through Industry Collaboration
Privia Health's colorectal cancer screening program, supported by Amalgam Rx and Exact Sciences, achieved an 84% screening rate in 2024, surpassing national goals. The program utilized EHR-enabled workflows and proactive patient outreach to enhance screening accessibility. Launched in 2023, it aims to improve preventive care initiatives while reducing administrative burdens for healthcare providers.
Read more →-PRVA
Feb 26, 2026▲ +10%on this news
Privia Health Reports Fourth Quarter and Full-Year 2025 Financial Results
Privia Health Group, Inc. announced its financial results for Q4 and full year 2025, showcasing strong performance metrics that exceeded guidance. The company reported a 49.5% increase in net cash provided by operating activities compared to 2024, alongside a solid balance sheet with no debt. Looking ahead, Privia aims to maintain its growth trajectory in 2026.
Read more →-PRVA
Jan 22, 2026Privia Health to Report Fourth Quarter 2025 Results on Thursday, February 26
Privia Health Group, Inc. will release its financial results for Q4 and the full year 2025 on February 26, 2026. The results will be available before market open, followed by a conference call to discuss the outcomes and future outlook. The company emphasizes its commitment to enhancing healthcare delivery.
Read more →-PRVA
Nov 6, 2025Privia Health Reports Third Quarter 2025 Financial Results - Very Strong Third Quarter and Year-to-Date Performance Across the Business - Net Income +94.1% and Adjusted EBITDA +61.6% compared to 3Q'24 - Implemented Provi
Privia Health Group, Inc. has reported strong financial results for the third quarter of 2025, revealing a 94.1% increase in net income and a 61.6% rise in adjusted EBITDA compared to the same period last year. The company has also raised its full-year 2025 guidance, reflecting expectations for continued growth across key metrics. Furthermore, Privia showcased a robust performance in its Medicare Shared Savings Program, achieving significant shared savings. The company is poised for further growth as it proceeds with the acquisition of an ACO business that will enhance its value-based care footprint.
Read more →-PRVA
Sep 23, 2025would," "could," "should," and variations of such terms and similar expressions and references to guidance, although some forward-looking statements may be expressed differently. In particular, these include statements r
Privia Health Group, Inc. announced its acquisition of an Accountable Care Organization (ACO) business from Evolent Health, which cares for over 120,000 attributed lives. This move will expand Privia's reach in value-based care arrangements, serving approximately 1.5 million attributed lives across various programs. The acquisition, costing $100 million with an additional $13 million based on performance, is expected to enhance Privia's Adjusted EBITDA in 2026. The transaction underscores Privia's strategy to integrate new providers into its extensive network and technology platform, aiming for improved patient outcomes and cost-effectiveness.
Read more →-PRVA
Aug 29, 2025▲ +5.6%on this news
financial and operational impact of our compliance with various complex and changing federal and state privacy and security laws and regulations related to our use, disclosure, and other processing of personal informatio
Privia Health Group, Inc. reported impressive results from its Accountable Care Organizations (ACOs) in the 2024 Medicare Shared Savings Program, achieving over $233 million in shared savings, marking a 32% increase from the previous year. The firm's Mid-Atlantic ACO delivered the highest savings rate of 10.6%, showcasing the effectiveness of its physician-led model. Additionally, the company has raised its Adjusted EBITDA guidance for full-year 2025 to between $113 to $116 million, reflecting its strong operational performance and growth strategy.
Read more →-PRVA
Aug 7, 2025Privia Health Reports Second Quarter 2025 Financial Results - Very Strong First Half Performance Across All Key Operating and Financial Metrics - Implemented Providers +13.8% and Practice Collections +18.5% compared to 2
Privia Health Group, Inc. has reported strong financial results for the second quarter of 2025, showcasing a total revenue increase of 23.4% compared to the same quarter in 2024. Key metrics such as practice collections and adjusted EBITDA saw significant growth, leading the company to raise its financial guidance for the full year 2025. Despite the positive performance, there was a noted decline in operating income and net income compared to last year. Overall, the results reflect continued strength in the company's services and expansion strategy.
Read more →-PRVA
Jul 8, 2025does not undertake any obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as may be required under applicable securities laws. Contac
Privia Health Group, Inc. has appointed Lance V. Berberian to its Board of Directors, effective July 15, 2025. Berberian, who has over 30 years of experience in technology strategy and cybersecurity, will also serve on the Audit Committee. His appointment increases the board's composition to 10 members, and the company hopes to leverage his expertise for continued growth in building provider networks across the U.S. Privia Health focuses on transforming healthcare delivery to improve outcomes and lower costs.
Read more →-PRVA
May 8, 2025▲ +7.5%on this news
Privia Health Reports First Quarter 2025 Financial Results - Strong First Quarter Performance and Operating Execution - Enters the State of Arizona - Full-Year 2025 Outlook Raised to Mid- to High End of Guidance Ranges f
Privia Health Group, Inc. reported positive financial results for Q1 2025, with significant increases in revenue, gross profit, and operating income compared to the previous year. The company has entered the state of Arizona through a partnership with Integrated Medical Services, aiming to expand its provider network and manage more patient lives in value-based care arrangements. Additionally, Privia has raised its full-year guidance for 2025 to the mid- to high end of its previous projections, reflecting confidence in its operational performance and growth potential.
Read more →-PRVA
Feb 27, 2025▲ +5.8%on this news
Privia Health Reports Fourth Quarter and Full-Year 2024 Financial Results - All 2024 Operating and Financial Metrics Above High End of Guidance Ranges - Very strong New Provider Signings Implemented Providers +11.2% from
Privia Health Group, Inc. announced its financial results for the fourth quarter and full year of 2024, reporting that all operating and financial metrics surpassed the high end of their guidance ranges. Key highlights include a strong increase in new provider signings, which rose by 11.2% year-over-year, and a notable 35.3% increase in net cash provided by operating activities, totaling $109.3 million. However, the company experienced a decline in net income and operating income compared to the previous year. For 2025, Privia is focusing on provider growth and navigating a challenging Medicare Advantage environment while aiming for profitable growth.
Read more →-PRVA
Nov 7, 2024▲ +6.5%on this news
Privia Health Reports Third Quarter 2024 Financial Results - Strong Execution Across All Business and Financial Metrics - Raised Full-Year 2024 Guidance to At or Above the High End for All Metrics - Announced New Market
Privia Health Group, Inc. (Nasdaq: PRVA) announced its financial results for the third quarter and nine months ending September 30, 2024, showcasing strong performance across various business metrics. The company reported total revenue of $437.9 million, an increase of 4.9%, and adjusted EBITDA growth of 25.8%. Privia Health has raised its full-year 2024 guidance for key financial metrics, supported by the successful entry into the Indiana market. However, despite these successes, net income showed a significant decline of 37.4% year-over-year.
Read more →-PRVA
Aug 8, 2024▲ +5.9%on this news
Privia Health Reports Second Quarter 2024 Financial Results - Strong Execution Across All Business and Financial Metrics - Raised Full-Year 2024 Guidance to Mid to High End for All Metrics ARLINGTON, VA
Privia Health Group, Inc. reported its financial results for the second quarter and first six months of 2024, showcasing a revenue increase of 4.7% year-over-year and solid growth in adjusted EBITDA. Despite a declining net income and operating income, the company raised its full-year guidance across key financial metrics, reflecting confidence in its operational strategies. The financial health remains robust with significant cash reserves and a strong provider network.
Read more →-PRVA
May 9, 2024Privia Health Reports First Quarter 2024 Financial Results - Practice Collections +7.4% compared to 1Q'23 - Implemented Providers +17.3% compared to 1Q'23 - Company Reiterated Full Year 2024 Guidance ARLINGTON, VA
Privia Health Group, Inc. reported its financial results for the first quarter of 2024, showing a 7.5% increase in total revenue to $415.2 million, alongside strong growth in practice collections and implemented providers. The company successfully grew implemented providers by 17.3% year-over-year, while adjusted EBITDA increased by 18.1%. Despite these strong performance indicators, the company noted a significant decline in operating income and net income compared to the previous year. Privia reiterated its full-year guidance amid concerns regarding future practice collections due to renegotiated Medicare Advantage agreements.
Read more →-PRVA
Feb 27, 2024▲ +9.7%on this news
Privia Health Reports Fourth Quarter and Full-Year 2023 Financial Results - Achieved All 2023 Operating and Financial Guidance Metrics - Implemented Providers +19.4% compared to Year-End 2022 - Introduces Full-Year 2024
Privia Health Group, Inc. reported strong financial results for Q4 and the full year of 2023, achieving all its operational and financial guidance metrics. The company saw a 19.4% increase in implemented providers compared to the previous year-end, contributing to total revenue growth of 22.2%. However, they anticipate a decrease in practice collections by approximately $198 million in 2024 due to renegotiated contracts in the Medicare Advantage market. Additionally, Priva plans to enhance its position in existing markets while pursuing new growth opportunities.
Read more →-PRVA
Jan 29, 2024▼ -5.6%on this news
Privia Health Appoints Edward C. Fargis as General Counsel ARLINGTON, VA
Privia Health has appointed Edward C. Fargis as Executive Vice President, General Counsel, and Corporate Secretary. Fargis, who brings significant legal and leadership experience from his previous roles in the healthcare sector, will support the company's continued growth and strategic direction. He succeeds Thomas Bartrum, who will assist with the transition until May 31, 2024. The appointment comes at a crucial time for Privia Health as it aims to enhance its capabilities in optimizing physician practices and improving patient experiences.
Read more →-PRVA
Nov 3, 2023▲ +14.3%on this news
Privia Health Reports Third Quarter 2023 Financial Results Announces New Market Entry in South Carolina - Practice Collections +18.2% com pared to 3Q'22 - Implemented Providers +14.2% compared to 3Q'22 - Company Updated
Privia Health Group, Inc. reported strong financial results for Q3 2023, showing a revenue increase of 21.7% year-over-year. Net income for the quarter grew to $5.6 million, reflecting a turnaround from an operating loss in the previous year. The company announced its entry into South Carolina through a partnership with Greenville ENT and Allergy Associates, expected to launch in early 2024. Additionally, Privia updated its full-year guidance, projecting robust growth across key performance metrics.
Read more →-PRVA
Aug 3, 2023Privia Health Reports Second Quarter 2023 Financial Results - Practice Collections +13.7% compared to 2Q'22 - Implemented Providers +9.3% compared to 2Q'22 - Company Updated Full Year 2023 Guidance ARLINGTON, VA
Privia Health Group, Inc. reported its financial results for the second quarter of 2023, demonstrating a substantial increase in revenue, gross profit, and a shift from a net loss in the prior year to a net income of $7.3 million. The company also updated its full-year guidance, indicating optimism in its operational performance. Notable metrics included a year-over-year increase in practice collections by 13.7% and the addition of new providers. The company announced a partnership to expand into Washington State, signaling growth in its geographical footprint.
Read more →-PRVA
Jul 31, 2023Privia Health Announces Changes to Board of Directors Distinguished Healthcare Leader Dave Wichmann and Seasoned CHRO Pam Kimmet to Join Board ARLINGTON, VA
Privia Health has announced the election of Dave Wichmann and Pam Kimmet to its Board of Directors, effective August 1, 2023. Wichmann, former CEO of UnitedHealth Group, brings extensive experience in healthcare, while Kimmet contributes expertise in human resources from her roles at Manulife and Cardinal Health. The board changes aim to enhance Privia's strategic capabilities, focusing on improving patient outcomes and operational excellence in value-based care. Jeff Bernstein will resign from the board following Goldman Sachs' divestment from its stake in the company.
Read more →-PRVA
May 8, 2023Information Relating to Part II, Item 14. Other Expenses of Issuance and Distribution The following is a statement of the expenses incurred or expected to be incurred, other than underwriting discounts and commissions, t
Privia Health Group, Inc. has disclosed the expenses related to the issuance and distribution of its registered securities. The total estimated expenses amount to $595,185, which includes various fees such as legal, accounting, and printing costs. Notably, the largest portion of the expenses is attributed to legal fees totaling $250,000. The company has detailed these costs as part of its compliance with Securities and Exchange Commission regulations.
Read more →-PRVA
May 4, 2023Privia Health Reports First Quarter 2023 Financial Results - Practice Collections +17.3% compared to 1Q'22 - Implemented Providers +10.3% compared to 1Q'22 - Company Reiterated Full Year 2023 Guidance ARLINGTON, VA
Privia Health Group, Inc. reported strong financial results for the first quarter of 2023, with total revenue rising to $386.3 million, a 23.1% increase from the same period in 2022. The company also achieved practice collections growth of 17.3% and improved their net income from a loss of $(17.5) million in Q1 2022 to a profit of $7.3 million in the recent quarter. Additionally, Privia reiterated its full-year guidance, indicating a positive outlook for the remainder of the year.
Read more →-PRVA
Apr 12, 2023Privia Health Announces Leadership Succession Current President and COO Parth Mehrotra Named CEO Shawn Morris to Retire and Remain on Board of Directors ARLINGTON, VA
Privia Health has announced a leadership transition, naming Parth Mehrotra as the new CEO, effective July 1, 2023. He takes over from Shawn Morris, who will retire but remain on the company's Board of Directors. Under Morris' tenure, Privia expanded nationally and significantly increased its provider partnerships. Mehrotra expressed eagerness to lead the company through upcoming changes in the healthcare industry, continuing its focus on optimizing primary-care delivery networks.
Read more →-PRVA
Feb 28, 2023Privia Health Reports Fourth Quarter 2022 Financial Results - FY 2022 Financial Results At or Above High End of Guidance with Practice Collections Growth of 49.1% compared to FY 2021 - New Market Entries announced in Con
Privia Health Group, Inc. reported strong financial results for the fourth quarter and full year of 2022, achieving revenues of $364.4 million and a growth in practice collections by 49.1% compared to the previous year. The company also announced entry into four new markets including Connecticut, Delaware, North Carolina, and Ohio, while launching three new Accountable Care Organizations (ACOs). Despite a recovery in net income for Q4, the company experienced a full-year operating loss. The long-term vision includes building a large ambulatory care network, supported by new partnerships and growth strategies.
Read more →-PRVA
Nov 15, 2022Privia Health Announces Change to its Board of Directors ARLINGTON, VA
Privia Health Announces Change to its Board of Directors ARLINGTON, VA November 15, 2022 Privia Health Group, Inc. (Nasdaq: PRVA) today announced that Jeff Butler has resigned from the Company s Board of Directors and as a member of the Compliance Committee of the Board, effect
Read more →-PRVA
Nov 10, 2022▲ +11.9%on this newsshared move
Privia Health Reports Third Quarter 2022 Financial Results - Results and outlook reflect strong year-to-date performance and business momentum - Implemented Providers +27.2% compared to 3Q'21 - Practice Collections +52.4
Privia Health Reports Third Quarter 2022 Financial Results -Results and outlook reflect strong year-to-date performance and business momentum -Implemented Providers +27.2% compared to 3Q'21 -Practice Collections +52.4% compared to 3Q'21 -Shared savings of $100 million achieve
Read more →-PRVA
Aug 11, 2022Privia Health Reports Second Quarter 2022 Financial Results - Updated guidance reflects strong first half performance and continued business momentum - Practice Collections +67.6% compared to 2Q'21 - Implemented Provider
Privia Health Reports Second Quarter 2022 Financial Results -Updated guidance reflects strong first half performance and continued business momentum -Practice Collections +67.6% compared to 2Q'21 -Implemented Providers +31.5% compared to 2Q'21 -Repaid all outstanding debt in
Read more →-PRVA
May 12, 2022▲ +10.6%on this news· ran to +28% by day 1
Privia Health Reports First Quarter 2022 Financial Results - Updated financial guidance reflects strong Q1 performance and business momentum - Practice Collections +63.3% compared to 1Q'21 - Implemented Providers +27.3%
Privia Health Reports First Quarter 2022 Financial Results -Updated financial guidance reflects strong Q1 performance and business momentum -Practice Collections +63.3% compared to 1Q'21 -Implemented Providers +27.3% compared to 1Q'21 -Value-Based Care Attributed Lives +17.6%
Read more →-PRVA
Mar 31, 2022Nancy Cocozza Joins Privia Health's Board of Directors ARLINGTON, VA
Nancy Cocozza Joins Privia Health's Board of Directors ARLINGTON, VA - March 31, 2022 - Privia Health Group, Inc. (Nasdaq PRVA) today announced the addition of Nancy Cocozza to its Board of Directors, increasing its Board to ten members. Ms. Cocozza, a former senior vice preside
Read more →-PRVA
Mar 23, 2022Privia Health Reports Fourth Quarter 2021 Financial Results - FY 2021 Financial Results Above High End of Guidance - FY 2022 Guidance Highlights Practice Collections Growth of 30.7% at Midpoint - Entries into California,
Privia Health Reports Fourth Quarter 2021 Financial Results -FY 2021 Financial Results Above High End of Guidance -FY 2022 Guidance Highlights Practice Collections Growth of 30.7% at Midpoint -Entries into California, Montana and West Texas help to Accelerate 2022 Growth -Lau
Read more →-PRVA
Jan 10, 2022▲ +5.5%on this news
investorpresentatio PROPRIETARY AND CONFIDENTIAL J.P. Morgan Healthcare Conference
PROPRIETARY AND CONFIDENTIAL J.P. Morgan Healthcare Conference January 10, 2022 Empowering Physicians TRANSFORMING HEALTHCARE 2 Forward-Looking Statements This presentation contains forward-looking statements that express the Company's opinions, expectations, beliefs, plans, obj
Read more →-PRVA
Jan 6, 2022Jeff Sherman Joins Privia Health as Chief Financial Officer ARLINGTON, VA
Jeff Sherman Joins Privia Health as Chief Financial Officer ARLINGTON, VA - January 6, 2022 - Privia Health Group, Inc. (Nasdaq PRVA) announced that Jeffrey S. Sherman will join the company as Executive Vice President and Chief Financial Officer (CFO), effective immediately. Mr.
Read more →-PRVA
Dec 21, 2021▲ +5.5%on this news
Empowering Physicians TRANSFORMING HEALTHCARE Piper Sandler Value-Based Care Webinar
Value-Based Care Webinar December 21, 2021 PROPRIETARY AND CONFIDENTIAL Disclaimer Forward-Looking Statements This presentation contains forward-looking statements that express the Company's opinions, expectations, beliefs, plans, objectives, assumptions or projections regardin
Read more →-PRVA
Nov 8, 2021▲ +14.3%on this news
Privia Health Reports Third Quarter 2021 Financial Results - Raises Full-Year 2021 Guidance on All Metrics - Record New Provider Growth - Strong Performance in 2020 MSSP and Other Value-based Programs - Entry into Califo
Privia Health Reports Third Quarter 2021 Financial Results -Raises Full-Year 2021 Guidance on All Metrics -Record New Provider Growth -Strong Performance in 2020 MSSP and Other Value-based Programs -Entry into California and West Texas Markets to Accelerate Growth ARLINGTON,
Read more →-PRVA
Aug 9, 2021Privia Health Reports Second Quarter 2021 Financial Results ARLINGTON, VA
Privia Health Reports Second Quarter 2021 Financial Results ARLINGTON, VA - August 9, 2021 - Privia Health Group, Inc. (Nasdaq PRVA) today announced financial results for the second quarter and six-month periods ended June 30, 2021. Total revenue for the second quarter of 2021
Read more →-PRVA
Jun 30, 2021Dr. Jaewon Ryu Joins Privia Health's Board of Directors ARLINGTON, VA
Dr. Jaewon Ryu Joins Privia Health's Board of Directors ARLINGTON, VA - June 30, 2021 - Privia Health Group, Inc. (Nasdaq PRVA) today announced that Jaewon Ryu, MD, JD, has been elected to the Company's Board of Directors, effective immediately. In connection with this election,
Read more →-PRVA
May 27, 2021priviainvesto PROPRIETARY AND CONFIDENTIAL Investor Presentation June 2021 Empowering Physicians TRANSFORMING HEALTHCARE 2 Forward-Looking Statements This presentation contains forward-looking statements that express the
PROPRIETARY AND CONFIDENTIAL Investor Presentation June 2021 Empowering Physicians TRANSFORMING HEALTHCARE 2 Forward-Looking Statements This presentation contains forward-looking statements that express the Company's opinions, expectations, beliefs, plans, objectives, assumption
Read more →-PRVA
May 27, 2021Privia Health Reports First Quarter 2021 Financial Results ARLINGTON, VA
Privia Health Reports First Quarter 2021 Financial Results ARLINGTON, VA - May 27, 2021 - Privia Health Group, Inc. (Nasdaq PRVA), a technology-driven, national physician enablement company that collaborates with medical groups, health plans and health systems, today announced f
Read more →Competitive Position
How PRVA ranks across every disease it competes inCompetitive Position is a premium feature
See how PRVA ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial